19:12 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest combining MCL1 inhibitors with inducers of double-strand break stress could help treat NSCLC. In an irradiated human NSCLC cell line, MCL1 knockout decreased repair...
00:39 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); multiple myeloma (MM) In vitro and cell culture studies suggest stapled peptide inhibitors of MCL1 could help treat ALL and MM. Modification of previously identified peptide-based inhibitors of MCL1 with hydrocarbon...
19:14 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2-amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher in TNBC...
14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); lymphoma; multiple myeloma (MM) In vitro and mouse studies identified an MCL1 inhibitor that could help treat AML, lymphoma and MM. NMR-based fragment screening, chemical synthesis and optimization, and in vitro...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

Cancer INDICATION: Breast cancer Patient sample and cell studies suggest inhibiting EIF4B or MCL1 could help treat basal breast cancer. In tumor samples from breast cancer patients, MCL1 levels were higher in the aggressive basal breast cancer...